Paucimannosidic glycoepitopes inhibit tumorigenic processes in glioblastoma multiforme
Metrics: PDF 97 views | HTML 132 views | ?
Yvonne Becker1,*, Sarah Förster1,*, Gerrit H. Gielen2, Ian Loke3, Morten Thaysen-Andersen3, Christine Laurini1, Kristin Wehrand1, Torsten Pietsch2 and Simone Diestel1
1 Institute of Nutrition and Food Sciences, Department of Human Metabolomics, University of Bonn, Bonn 53115, Germany
2 Institute of Neuropathology, University of Bonn Medical Center, Bonn 53127, Germany
3 Department of Molecular Sciences, Macquarie University, Sydney, NSW 2109, Australia
* These authors contributed equally to this work
Keywords: cancer progression; glioblastoma multiforme; N-glycosylation; paucimannosidic epitopes; AHNAK
Received: April 05, 2019 Accepted: June 10, 2019 Published: July 09, 2019
Glioblastoma multiforme is an aggressive cancer type with poor patient outcomes. Interestingly, we reported previously a novel association between the little studied paucimannosidic N-linked glycoepitope and glioblastoma. Paucimannose has only recently been detected in vertebrates where it exhibits a very restricted tumor-specific expression. Herein, we demonstrate for the first time a very high protein paucimannosylation in human grade IV glioblastoma and U-87MG and U-138MG glioblastoma cells. Furthermore, we revealed the involvement of paucimannosidic epitopes in tumorigenic processes including cell proliferation, migration, invasion and adhesion. Finally, we identified AHNAK which is discussed as a tumor suppressor as the first paucimannose-carrying protein in glioblastoma and show the involvement of AHNAK in the observed paucimannose-dependent effects. This study is the first to provide evidence of a protective role of paucimannosylation in glioblastoma, a relationship that with further in vivo support may have far reaching benefits for patients suffering from this often fatal disease.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.